Similarly, hsa-miR-16-5p is a tumor inhibitor and a new biomarker for immune-checkpoint-inhibitor-dependent immunotherapy in lung adenocarcinoma by regulating the PD-L1 expression [35]. This evidence concerns the gene CD274 and neoplasm.